fbpx Can chronic migraine be prevented by targeting risk factors? | Progress In Mind

Can chronic migraine be prevented by targeting risk factors?

Many risk factors have been identified for predicting the transition from episodic to chronic migraine. Interventions to treat these risk factors have, however, not been studied, but are still worth considering and implementing for patients with episodic migraine, said Professor Richard Lipton, Albert Einstein College of Medicine, CT, at the Virtual Scottsdale Headache Symposium 2020.

Migraine is a common chronic disorder with episodic attacks, said Professor Richard Lipton, Albert Einstein College of Medicine, CT.

Treating risk factors might prevent progression to chronic migraine

In the United States, the prevalence of migraine is 18% among women and 6% in men;1 and every year, episodic migraine progresses to chronic migraine in 2.5% of patients,2 he explained.

Many risk factors have been identified for predicting this transition3–10 and treating them might therefore prevent progression. Although such interventions have not been studied, they are still worth considering and implementing, said Professor Lipton.

 

Important to address poor response to acute treatment and depression

Inadequate acute treatment efficacy is associated with an increased risk of new-onset chronic migraine, with rates of 1.9%, 2.7%, 4.4% and 6.8% over 1 year among those with maximal, moderate, poor, and very poor treatment efficacy, respectively.11

Improving acute treatment outcomes might therefore prevent new-onset chronic migraine, commented Professor Lipton. This also lowers the risk of medication overuse,9 which is another risk factor.

Furthermore, barbiturates and opiates, which are pharmacologic treatment options for acute episodic migraine, are associated with an increased conversion rate to chronic migraine,2 so alternative therapies are recommended to avoid this risk.

Depression is a prognostic factor for migraine

Severity of depression also predicts increased risk for new-onset chronic migraine over the following year with OR=1.77 (95% CI 1.25–2.52) for moderate depression, OR=2.35 (95% CI 1.53–3.62) for moderately severe depression, and OR=2.53 (95% CI 1.52–4.21) for severe depression.12

Effective treatment of depression might therefore lower the risk for chronic migraine, said Professor Lipton.

 

Interventions to address other risk factors

Professor Lipton also enumerated the following risk factors for progression and the interventions that might prevent chronic migraine:

  • attack frequency3—reduce frequency with pharmacologic and behavioral interventions
  • obesity3—manage with weight loss, exercise and bariatric surgery
  • comorbidities including depression and anxiety4—address with pharmacologic and behavioral therapies
  • major life events5—implement biobehavioral techniques and exercise for associated stress
  • snoring6—improve with weight loss and treatment of sleep apnea
  • caffeine7—lower intake
  • allodynia8—ensure early recognition and treatment

Efforts to address barriers to care are needed to improve outcomes

Low socioeconomic status4 and head injury10 are further risk factors.

Professor Lipton highlighted that among people with migraine in need of medical care, only 25% traverse the three steps needed—consultation, diagnosis, and treatment/medication use—to achieve minimally appropriate care.13 Barriers to care also need to be addressed to improve outcomes, he concluded.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. Lipton RB, et al. Neurology 2007;68:343–9.
  2. Bigal ME, et al. Headache 2008;48:1157–68.
  3. Scher AI, et al. Pain 2003;106:81–9.
  4. Buse DC, et al. J Neurol Neurosurg Psychiatry 2010;81:428–32.
  5. Couch JR, et al. Neurology 2007;69:1169–77.
  6. Scher AI, et al. Neurology 2003;60:1366–8.
  7. Scher AI, et al. Neurology 2004;63:2022–7.
  8. Lipton RB, et al. Ann Neurol 2006;63:1498–58.
  9. Scher AI, et al. Cephalalgia 2008;28:868–76.
  10. Buse DC, et al. Headache 2019;59:306–38.
  11. Lipton RB, et al. Neurology 2015;84:688–95.
  12. Ashina S, et al. J Headache Pain 2012;13:615–24.
  13. Lipton RB, et al. Headache 2013;53:81–92.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country